

18 December 2023

## Osteopore secures approval in Hainan for neurosurgery products to boost Chinese expansion

### Highlights

- Osteopore secures approval to supply neurosurgery products to Ruijin Hospital in Hainan – an affiliate of the globally renowned Shanghai Jiao Tong University School of Medicine.
- This approval represents a key milestone in Osteopore's quest to grow its China footprint and expand its global presence.

**Osteopore Limited (ASX: OSX; Osteopore or Company)**, a global regenerative medicine company founded in Singapore and listed in Australia, is delighted to announce that it has secured approval from the Hainan Medical Product Administration, for the use of the Company's neurosurgery products at Ruijin Hospital in China's Hainan Boao Lecheng International Medical Tourism Pilot Zone.

This approval is a key milestone in the Company's expansion into China and the delivery of one of Osteopore's mature neurosurgical products, Osteoplug. Ruijin Hospital is affiliated with Shanghai Jiao Tong University School of Medicine, which is frequently ranked #1 among medical schools in China<sup>1</sup>, while being ranked #62 globally by the US News & World Report<sup>2</sup>.

The Hainan Boao Lecheng Pilot Zone was launched to support the Healthy China 2030<sup>3</sup> plan. By 2025, the Pilot Zone is expected to draw more than 2 million people seeking medical

<sup>1</sup> "Overview-Shanghai Jiaotong University School of Medicine" [www.shsmu.edu.cn](http://www.shsmu.edu.cn)

<sup>2</sup> "Best Global Universities for Clinical Medicine" <https://www.usnews.com/education/best-global-universities/china/clinical-medicine>

<sup>3</sup> <https://www2.deloitte.com/content/dam/Deloitte/cn/Documents/life-sciences-health-care/deloitte-cn-lshc-china-health-ecosystem-2030-en-220623.pdf>

treatment – including 0.5 million people who could have chosen overseas medical services. The Company also has the option of collecting real-world clinical data in Hainan to provide supplementary clinical data for an upcoming submission to the National Medical Products Administration (NMPA) – which could potentially expedite registration in mainland China.

**Commenting on Osteopore’s progress into Hainan, Osteopore CEO Jing Lim said:**

“This important milestone is the culmination of months of hard work by our regulatory team and our distributor Kontour Medical Technology Co. Ltd, both of whom have demonstrated excellent professionalism and expertise in navigating the process.

We look forward to a series of cases in the near term and aim to develop Key Opinion Leaders throughout this process. Being associated with a hospital that is affiliated with the #1 medical school in China is essential to positioning our products.”

**ENDS**

*This announcement dated 18 December 2023 has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Mark Leong**

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: [mark\\_leong@osteopore.com](mailto:mark_leong@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: [istewart@canningspurple.com.au](mailto:istewart@canningspurple.com.au)

**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia aiming to commercialise products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time only to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.